Blockchain Registration Transaction Record

Annovis Bio Secures Patent for Breakthrough Neurodegenerative Treatment

Annovis Bio expands IP for buntanetap, a neurodegenerative disease treatment, with patents secured until 2046. A breakthrough for AD and PD patients.

This news is crucial for patients, caregivers, and investors in the biotech sector. Annovis Bio's advancement in neurodegenerative disease treatment represents a significant step forward in addressing conditions like Alzheimer’s and Parkinson’s, which affect millions worldwide. The extended patent protection ensures the company's ability to develop and potentially bring to market a treatment that could improve patient outcomes and quality of life. For investors, this underscores Annovis Bio's position as a key player in the biotech industry, with a robust pipeline and intellectual property portfolio.